oxycodone - Profile

What are the generic sources for oxycodone and what is the scope of freedom to operate?

Oxycodone is the generic ingredient in six branded drugs marketed by Collegium Pharm Inc, Ani Pharms, Avanthi Inc, Dr Reddys Labs Sa, Genus Lifesciences, Lannett Co Inc, Novel Labs Inc, Abhai Llc, Alkem Labs Ltd, Ascent Pharms Inc, Aurolife Pharma Llc, Chartwell Molecular, Hibrow Hlthcare, Hikma, Pharm Assoc, Pharmobedient, Quagen, Rhodes Pharms, Specgx Llc, Vistapharm Llc, Purdue Pharma Lp, Roxane, Zyla, Actavis Elizabeth, Alvogen, Amneal Pharms, Epic Pharma Llc, Nesher Pharms, Nuvo Pharm, Strides Pharma Intl, Sun Pharm Inds Inc, and Protega Pharms, and is included in fifty-three NDAs. There are twenty-five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oxycodone has twenty-four patent family members in thirteen countries.

There are four tentative approvals for this compound.

Summary for oxycodone

International Patents:	24
US Patents:	25
Tradenames:	6
Applicants:	32
NDAs:	53
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for oxycodone

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for oxycodone

Constraining patent/regulatory exclusivity:

7,771,707

Dosage:

CAPSULE, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for OXYCODONE

Applicant	Application No.	Strength	Dosage Form
		80MG	TABLET, EXTENDED RELEASE; ORAL
		80MG	TABLET, EXTENDED RELEASE; ORAL
		40MG	TABLET, EXTENDED RELEASE; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for OXYCODONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XTAMPZA ER	Extended-release Capsules	oxycodone	9 mg, 13.5 mg, 18 mg, 27 mg and 36 mg	208090	1	2017-11-15

US Patents and Regulatory Information for oxycodone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No	10,004,729		Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No	10,188,644		Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No	10,646,485		Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No	9,968,598		Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No	9,682,075		Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No	10,668,060		Y
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016		RX	Yes	No	9,737,530		Y

Expired US Patents for oxycodone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016	9,248,195
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016	9,248,195
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016	9,592,200
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-002	Apr 26, 2016	9,044,398
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016	7,399,488
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-001	Apr 26, 2016	7,399,488
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-004	Apr 26, 2016	8,758,813

International Patents for oxycodone

Country	Patent Number	Title	Estimated Expiration
Japan	2015166402	オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物 (ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS)
Japan	2015166402	オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物 (ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS)
Japan	4694207
Slovenia	1765292
Canada	2916869	FORMULATIONS DE PREVENTION DES ABUS (ABUSE-DETERRENT DRUG FORMULATIONS)
World Intellectual Property Organization (WIPO)	2005123039
Japan	4694207

Supplementary Protection Certificates for oxycodone

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

Oxycodone: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Oxycodone, a potent semi-synthetic opioid analgesic primarily used for pain management, is subject to complex market dynamics influenced by regulatory constraints, litigation, therapeutic demand, and public perception. Despite being widely prescribed, its legal and societal risks create a volatile investment environment. This report examines oxycodone’s current market landscape, potential growth trajectories, regulatory considerations, key players, and future outlooks to assist stakeholders in strategic decision-making.

---

1. Introduction

Oxycodone is a Schedule II controlled substance in the United States, classified under the Controlled Substances Act due to its high potential for abuse and addiction. Its patent history, manufacturing landscape, and regulatory environment influence its market trajectory.

Key points:

• Market size: Estimated global sales of oxycodone products exceeded $6 billion in 2022, with the U.S. accounting for approximately 80%.
• Patents: Many formulations now are generic, reducing profitability potential but increasing volume.
• Regulatory environment: Ongoing litigation, abuse deterrent formulations, and prescription guidelines shape market access.

---

2. Market Dynamics

2.1 Demand Drivers

Factor	Impact	Details
Medical Use	Primary driver	Chronic and acute pain management.
Population Demographics	Aging populations increase demand	More patients suffering from chronic pain conditions.
Opioid Prescribing Trends	Influences supply and usage	Post-2016 opioid prescribing restrictions have led to fluctuating demand.

2.2 Supply Chain and Manufacturing

Aspect	Implication	Notes
Patent Expiration	Increased generics availability	Multiple formulations have lost patent protection, leading to price erosion.
Manufacturing Concentration	Supply risks	Few large players dominate production, creating vulnerability.
Illicit Market Influence	Market diversion	Illicit manufacturing and trafficking impact public health and regulatory response.

2.3 Regulatory and Legal Landscape

Policy Element	Effect	Details
Government Regulations	Usage restrictions	CDC guidelines (2016) promote caution, affect prescribing rates.
Litigation	Market uncertainty	Thousands of lawsuits alleging over-prescription and misconduct.
Abuse-Deterrent Formulations	Market evolution	Development aimed to reduce misuse, possibly affecting sales volumes.

---

3. Financial Outlook and Trajectory

3.1 Revenue and Profitability Trends

Metric	2018	2019	2020	2021	2022	Notes
Global sales (USD)	$6.2B	$6.3B	$6.4B	$6.2B	$6.1B	Slight decline amid regulatory pressure.
Top manufacturers' margins	~20%	~18%	~17%	~16%	~15%	Erosion due to generics and regulatory costs.
Price per unit (average)	-	-	-	-	-	Decreased due to generic competition.

3.2 Investment Opportunities and Risks

Opportunities	Risks
Market demand persists for pain management	Regulatory crackdowns and potential bans
Development of abuse-deterrent formulations	Litigation liabilities and settlement costs
Entry into emerging markets with less regulation	Societal backlash and impact on pharmaceutical reputation

3.3 Future Forecasts

Scenario	2023–2027 Revenue Projection	Key Assumptions
Optimistic	$6.5–$7.0 billion	Continued demand, successful deterrent formulations, minimal reforms
Moderate	$5.8–$6.2 billion	Regulation tightening, declining prescriber acceptance
Pessimistic	<$5.0 billion	Widespread bans, strong societal pushback, legal penalties

---

4. Key Players and Patent Landscape

Company	Market Share (2022)	Key Products	Notable Patent Status
Purdue Pharma	~30%	OxyContin (original), reformulations	Bankruptcy settled; patent expirations ongoing
Teva Pharmaceuticals	~20%	Generic oxycodone products	Dominant in generic sector
Sun Pharmaceutical	~10%	Generic formulations	Expired or near-expiry patents
Other competitors	~40%	Multiple generic manufacturers	Variability in patent statuses

---

5. Policy and Ethical Considerations

• Prescription Guidelines: CDC’s 2016 guidelines promote cautious prescribing, impacting sales.
• Abuse Prevention: Ongoing development of abuse-deterrent formulations increases R&D costs but seeks to mitigate societal backlash.
• Legal Exposure: Thousands of lawsuits threaten financial stability; recent settlements include multi-billion dollar agreements.
• Public Health Impact: Stringent regulations aim to combat the opioid epidemic but may restrict legitimate access.

---

6. Comparative Analysis with Similar Drugs

Drug	Category	Market Size (2022)	Regulatory Stringency	Abuse Deterrent Formulations	Legal Risks
Morphine	Opioid analgesic	$2.1B	Moderate	Yes	Low
Hydrocodone	Opioid combination	$4.0B	High	Yes	Moderate
Fentanyl	Opioid potency	$12.0B	Very high	Yes	Very high

---

7. Investment Considerations and Strategic Outlooks

• Pharmaceutical Manufacturers: Focus on reformulation and abuse-deterrent strategies.
• Investors: Monitor legal developments and regulatory trends for risk management.
• Policymakers: Balance pain management needs with addiction mitigation.

---

8. FAQs

Q1: How does patent expiry influence oxycodone market profitability?
A: Patent expirations typically lead to increased generic competition, reducing product prices and profit margins but expanding volume.

Q2: What are the primary legal liabilities associated with oxycodone?
A: Manufacturers face lawsuits alleging over-prescription, misrepresentation, and inadequate warnings, leading to significant settlement costs.

Q3: How do regulatory changes impact oxycodone sales?
A: Stricter prescribing guidelines and abuse-deterrent requirements tend to reduce overall demand but improve product safety profiles.

Q4: What role do abuse-deterrent formulations play in the future of oxycodone?
A: They are central to reformulation efforts aimed at reducing misuse, potentially allowing continued market presence amid regulatory pressures.

Q5: Are emerging markets significant in oxycodone growth projections?
A: Yes, markets with less regulatory rigor could represent growth opportunities, though societal and legal hurdles persist.

---

9. Key Takeaways

• The oxycodone market remains sizeable but is increasingly volatile due to regulatory and legal pressures.
• Generics continue to erode pricing power, with profitability hinging on formulating abuse-deterrent versions.
• Litigation risks pose existential threats; companies must balance legal risk mitigation with market strategies.
• Future growth hinges on reformulations, expanding into emerging markets, and navigation of ongoing policy reforms.
• Stakeholders should closely monitor legislative developments, public health policies, and societal attitudes towards opioids.

---

10. References

[1] Centers for Disease Control and Prevention (CDC), 2016. "CDC Guideline for Prescribing Opioids for Chronic Pain."
[2] IQVIA, 2022. "Global Opioid Market Report."
[3] U.S. Department of Justice, 2022. "Opioid Litigation and Settlement Data."
[4] FDA, 2021. "Guidance for Abuse-Deterrent Opioids."
[5] Statista, 2023. "Opioid Market Revenue & Forecasts."